$INBS
INTELLIGENT BIO SOLUTIONS INC.
CIK:0001725430|SEC Filings
Consolidated Statements of Cash Flows - USD ($) |
12 Months Ended | |
|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Cash flows from operating activities | ||
| Net loss | $ (12,468,672) | $ (10,604,886) |
| Adjustments to reconcile net loss to cash used in operating activities: | ||
| Depreciation and amortization | 1,163,847 | 1,207,875 |
| Impairment of long-lived assets | 298,555 | 220,062 |
| Provision for credit losses | 9,974 | 546 |
| Inventory write-downs | 62,044 | |
| Stock-based compensation | 195,208 | 238,045 |
| Non-cash adjustment on R&D expenditure claims | 124,924 | (137,696) |
| Non-cash other operating activities | (87,933) | 119,519 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (253,850) | (164,910) |
| Inventories | 216,638 | 142,322 |
| Grant receivable / deferred grant income | (2,486,668) | |
| Research and development tax incentive receivable | (72,543) | (209,076) |
| Other current assets | (203,956) | (329,404) |
| Accounts payable and accrued expenses | (684,743) | 2,577,151 |
| Long-term employee benefit liabilities | (34,990) | 21,306 |
| Operating lease liabilities | (191,725) | (271,499) |
| Net cash used in operating activities | (11,927,222) | (9,677,313) |
| Cash flows from investing activities | ||
| Proceeds from sale of assets held for sale | 40,158 | |
| Purchase of property and equipment | (125,731) | (231,838) |
| Net cash used in investing activities | (85,573) | (231,838) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock, net of issuance costs | 10,699,794 | 4,589,866 |
| Proceeds from issuance of common stock for warrants exercised, net of issuance costs | 4,283,912 | 7,939 |
| Net cash provided by financing activities | 14,983,706 | 4,597,805 |
| Effect of foreign exchange rates on cash and cash equivalents | 1,492 | 27,157 |
| Net increase (decrease) in cash and cash equivalents | 2,972,403 | (5,284,189) |
| Cash and cash equivalents, beginning of period | 1,019,909 | 6,304,098 |
| Cash and cash equivalents, end of the period | 3,992,312 | 1,019,909 |
| Non-cash investing and financing activities | ||
| Equity issuance costs in accounts payable and accrued expenses | 14,999 | |
| Operating lease assets obtained in exchange for operating lease liabilities | 1,928,398 | |
| Issuance of common stock upon cashless exercise of Series F warrants | $ 55 | |
Consolidated Balance Sheets - USD ($) |
Jun. 30, 2026 |
Jun. 30, 2025 |
|||||
|---|---|---|---|---|---|---|---|
| Current assets | |||||||
| Cash and cash equivalents | $ 3,992,312 | $ 1,019,909 | |||||
| Accounts receivable, net | 848,464 | 594,614 | |||||
| Inventories, net | 418,577 | 635,215 | |||||
| Research and development tax incentive receivable | 806,951 | 734,408 | |||||
| Assets held for sale | 327,500 | ||||||
| Prepaid expenses and other current assets | 1,030,932 | 826,976 | |||||
| Total current assets | 7,097,236 | 4,138,622 | |||||
| Property and equipment, net | 294,399 | 251,325 | |||||
| Operating lease right-of-use assets | 1,751,040 | 69,520 | |||||
| Intangibles, net | 2,799,161 | 3,790,319 | |||||
| Total assets | 11,941,836 | 8,249,786 | |||||
| Current liabilities | |||||||
| Accounts payable and accrued expenses | 4,130,213 | 4,534,246 | |||||
| Current portion of operating lease liabilities | 147,005 | 84,659 | |||||
| Current employee benefit liabilities | 651,706 | 534,990 | |||||
| Notes payable | 197,146 | ||||||
| Total current liabilities | 4,928,924 | 5,351,041 | |||||
| Employee benefit liabilities, less current portion | 49,931 | 84,921 | |||||
| Operating lease liabilities, less current portion | 1,672,155 | ||||||
| Total liabilities | 6,651,010 | 5,435,962 | |||||
| Commitments and contingencies (Note 15) | |||||||
| Shareholders’ equity | |||||||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 2,905,615 and 2,905,603 shares issued and outstanding, as of June 30, 2026, respectively; 732,339 and 732,327 shares issued and outstanding, as of June 30, 2025, respectively | [1] | 29,056 | 7,324 | ||||
| Treasury stock, at cost, 12 shares as of June 30, 2026 and 2025, respectively | [1] | (1) | (1) | ||||
| Additional paid-in capital | [1] | 80,992,006 | 65,849,822 | ||||
| Accumulated deficit | (74,964,040) | (62,533,065) | |||||
| Accumulated other comprehensive loss | (546,186) | (327,944) | |||||
| Total consolidated Intelligent Bio Solutions Inc. equity | 5,510,835 | 2,996,136 | |||||
| Non-controlling interest | (220,009) | (182,312) | |||||
| Total shareholders’ equity | 5,290,826 | 2,813,824 | [2] | ||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ 11,941,836 | $ 8,249,786 | |||||
| |||||||